RE:Trogarzo IV push “Zhongyu announced today that 22 patients were recruited in 5 test sites in the United States. The subjects first received a biweekly intravenous drip of Trogarzo, and then switched to a biweekly intravenous bolus.
Zhongyu pointed out that there were no serious adverse reactions in this trial, and drug-related adverse reactions were mild to moderate, and there was no obvious trend of abnormal test data. After intravenous infusion of diluted drugs and intravenous boluses of undiluted drugs, the area under the drug concentration-time curve (AUC) of the two injections is similar. The 90% confidence interval of the AUC ratio of the two injection methods is 0.9478 to 1.1226, which is much narrower than Target value.
Zhongyu pointed out that it is expected to submit a drug certificate application to the US FDA as soon as possible within one month. “
https://technews.tw/2021/09/19/tai-med-new-medicine-for-aids/